GlassScriptPhysician profile
Tammye Willis
NPI 1598279788
$629.35
in general payments reported to CMS, 2019-2025
17 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.18 · 2024: $248 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $174.37 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $63.25 | 2024-2025 | Rexulti |
| Pfizer INC. | $57.13 | 2024-2025 | |
| Exact Sciences Corporation | $54.35 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $41.03 | 2024-2025 | Airsupra |
| Phathom Pharmaceuticals, INC. | $30.51 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $26.01 | 2025 | Auvelity |
| Optinose US, INC. | $24.84 | 2024 | |
| Astellas Pharma US INC | $21.36 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $19.74 | 2025 | |
| Boston Scientific Corporation | $18.94 | 2021 | |
| Lilly USA, LLC | $17.91 | 2024 | Zepbound, Mounjaro |
| Genentech USA, INC. | $17.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.73 | 2025 | |
| Abbvie INC. | $16.56 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $16.09 | 2024 | |
| Amgen INC. | $13.29 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammye Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.